Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulointerstitial nephritis antigen (TINAG) is an extracellular matrix glycoprotein encoded by the TINAG gene, primarily restricted to basement membranes in the kidney, including the epithelium of Bowman’s capsule and both proximal and distal tubules. Originally identified as a target antigen for autoantibodies in some forms of immunologically mediated tubulointerstitial nephritis, it plays a selective role in renal tubule development (tubulogenesis) without affecting glomerulogenesis. TINAG mediates cell-matrix adhesion by interacting with integrins (notably α3β1 and αvβ3), but unlike many matrix proteins lacks an RGD sequence. Expression of TINAG is developmentally regulated in the kidney, with evidence that disruption (e.g., by antibodies or developmental antisense knockdown) leads to tubular dysmorphogenesis and impaired renal development. Its main clinical significance is as an autoantigen in autoimmune kidney disorders, particularly tubulointerstitial nephritis and anti-glomerular basement membrane nephritis[1][2][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulointerstitial nephritis antigen (TINAG).